Tag Archives: Immuno-Oncology

Immuno-Oncology: The Comeback Kid
July 13, 2021

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4)

Leave a comment

Getting Personal at ASCO 2017: Precision Therapies, IO, and Autologous Cell Therapy
June 13, 2017

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. The 2017 American Society of Clinical Oncology (“ASCO”) meeting concluded last week, providing patients, physicians, and industry stakeholders with

1 Comment

I/O: The Strategic Supernova In Cancer Today
June 22, 2016

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,

3 Comments

ASCO 2015: Abstract Thoughts On Cancer And Competition
May 29, 2015

With the start of the American Society of Clinical Oncology meeting, all eyes in the biopharma investor community are on Chicago. Social media is alive with #ASCO15 tweets and companies big and small are firing out press releases. Signal from

2 Comments

It’s The Antigens, Stupid
April 27, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. “A big asset of VC’s is pattern recognition. It is also often our biggest liability.”  An apt observation tweeted by

1 Comment

Immuno-Oncology: Scratching the Surface
January 8, 2015

Another day, another announcement about great data from immuno-oncology.  It’s clearly one of the hottest fields in biopharma today, and has been for a few years.  The opening paragraph of a recent Leerink report by Seamus Fernandez and team on

1 Comment

Cellular Immunotherapy & Unum Therapeutics: Out of Many, One
October 21, 2014

More exciting news has emerged from the immuno-oncology field over the past couple weeks from both Penn/Novartis and NCI/Kite.  The former released new CAR-T data, widely heralded as “unprecedented” in its efficacy: in a trial of relapsed, refractory ALL patients,

3 Comments

Fueling Up To Attack Cancer: Two Big Startup Financings
October 14, 2014

Immuno-oncology, antibody-drug conjugates, and cancer metabolism are three of the hottest and potentially most transformative approaches in cancer research today, and have occupied center stage at recent oncology meetings like ASCO and AACR (here, here). The immuno-oncology (I/O) field has

Leave a comment

Immuno-Oncology Startup CoStim Pharmaceuticals Acquired By Novartis
February 18, 2014

Today Novartis announced its acquisition of CoStim Pharmaceuticals, a young biotech company focused on next generation approaches in the exciting immuno-oncology field (here).  Their oncology capabilities and commitment to anti-cancer immune mechanisms made them an ideal partner for us at

Leave a comment